SCHEMBL6073476

SCHEMBL6073476

CN1C(=O)C(C)(C)c2ccc(Cl)nc21

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.38
MARK3 P27448 2/20 0.36
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ELANE P08246 1/20 0.33
PDE4A P27815 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33
PDE4D Q08499 2/20 0.33
PGR P06401 3/20 0.32
HTR2A P28223 2/20 0.31
HTR2C P28335 2/20 0.31
HTR2B P41595 2/20 0.31
KCNH2 Q12809 1/20 0.31
POLB P06746 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
TDP2 O95551 1/20 0.30
NSD2 O96028 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15579018 0.81 MARK3 (0.35) LCKMARK3MEN1KMT2APDE4A
SCHEMBL18850851 0.81 MARK3 (0.36) LCKMARK3MEN1KMT2APDE4A
SCHEMBL6073645 0.77 IDH1 (0.35) LCKMARK3PGRHTR2AHTR2C
SCHEMBL17138115 0.76 MARK3 (0.47) LCKMARK3HTR2AHTR2CHTR2B
SCHEMBL18850888 0.72 MEN1 (0.33) LCKMARK3MEN1KMT2AELANE
SCHEMBL3519201 0.70 LMNA (0.37) MARK3PDE4APDE4BPDE4CPDE4D
SCHEMBL15579173 0.69 SMN1; SMN2 (0.42) MARK3MEN1KMT2APOLB
SCHEMBL15578833 0.67 KDM4E (0.41) KMT2APOLBL3MBTL1
SCHEMBL12127091 0.65 TDP2 (0.41) TDP2NSD2
SCHEMBL16323426 0.64 MEN1 (0.38) MARK3MEN1KMT2APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3371174-B1 INDOLIN-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2021-03-17 EP disclosed
EP-3371174-A1 INDOLIN-2-ONE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-09-12 EP disclosed
US-20180251450-A1 INDOLIN-2-ONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-09-06 US disclosed
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 US disclosed
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 US disclosed
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 US disclosed
EP-3027601-B1 SYK INHIBITORS GILEAD SCIENCES INC (US) 2017-10-25 EP disclosed
EP-3027601-B1 SYK INHIBITORS GILEAD SCIENCES INC (US) 2017-10-25 EP disclosed
WO-2017076842-A1 INDOLIN-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2017-05-11 WO disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 US disclosed
WO-2015017610-A1 SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2015-02-05 WO disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 US disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 US disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 US disclosed
WO-2015017610-A1 SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2015-02-05 WO disclosed
WO-2014040969-A1 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2014-03-20 WO disclosed
US-7119207-B2 Benzoamide piperidine containing compounds and related compounds PFIZER INC (US) 2006-10-10 US disclosed
US-20030087925-A1 Benzoamide piperidine containing compounds and related compounds PFIZER INC. 2003-05-08 US disclosed
EP-1272484-A2 BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS Pfizer Products Inc. (US) 2003-01-08 EP disclosed
WO-2001077100-A2 BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS PFIZER PRODUCTS INC. (US) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038488-A1 SYK INHIBITORS SYK, BTK, LYN LCK 4/4885MARK3 1315/4885MEN1 3234/4885
US-20180251450-A1 INDOLIN-2-ONE DERIVATIVES GRIN2B, GRIN2A, TPH2 LCK 1276/4885MARK3 1870/4885MEN1 1532/4885
US-20160368918-A1 SYK INHIBITORS SYK, BTK, LYN LCK 4/4885MARK3 1272/4885MEN1 3190/4885
US-20030087925-A1 Benzoamide piperidine containing compounds and related compounds TACR1, VIPR1, VIPR2 LCK 2883/4885MARK3 2443/4885MEN1 2361/4885
US-10005774-B2 Syk inhibitors SYK, BTK, LYN LCK 4/4885MARK3 1272/4885MEN1 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.